|
| Status |
Public on Feb 04, 2019 |
| Title |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Here we report the discovery of ABBV-744, a first in class, highly potent and selective inhibitor of BET family BD2 domains with drug like properties. RNA-seq analysis revealed that ABBV-744 elicited potent inhibition of AR-dependent transcription without causing broad transcription alterations associated with exposure to pan BET inhibitors.
|
| |
|
| Overall design |
mRNA profiles of LNCaP cells treated with ABBV-075, ABBV-744, or Enzalutmide in the presence or absence of DHT were generated by deep sequencing, in duplicate, using Illumina HiSeq3000.
|
| |
|
| Contributor(s) |
Faivre E, Hessler P, Lu X |
| Citation(s) |
31969702 |
| Submission date |
Aug 06, 2018 |
| Last update date |
Feb 19, 2020 |
| Contact name |
Xin Lu |
| E-mail(s) |
xin.x.lu@abbvie.com
|
| Phone |
847-937-7942
|
| Organization name |
Abbvie
|
| Department |
Oncology Discovery
|
| Street address |
1 North Waukegan Rd
|
| City |
North Chicago |
| State/province |
IL |
| ZIP/Postal code |
60064 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL21290 |
Illumina HiSeq 3000 (Homo sapiens) |
|
| Samples (10)
|
|
| This SubSeries is part of SuperSeries: |
| GSE130269 |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability |
|
| Relations |
| BioProject |
PRJNA484716 |
| SRA |
SRP156438 |
Less...
More...